Possible Warfarin Failure Due to Interaction with Smokeless Tobacco

Author:

Kuykendall Jim R1,Houle Michael D2,Rhodes Richard S3

Affiliation:

1. Jim R Kuykendall PhD PharmD, Assistant Professor of Biochemistry, Department of Biopharmaceutical Sciences, Raabe College of Pharmacy, Ohio Northern University, Ada, OH

2. Michael D Houle PharmD, Staff Clinical Pharmacist, Franciscan Health System, St. Claire Hospital, Lakewood, WA

3. Richard S Rhodes PharmD, Associate Professor, Department of Pharmacy Practice and Administrative Sciences, College of Pharmacy, Idaho State University, Pocatello, ID

Abstract

OBJECTIVE To report a case of possible interaction of smokeless tobacco with warfarin in a patient treated after several thromboembolic events. CASE SUMMARY A white man with a long history of smokeless tobacco use was unsuccessfully treated with warfarin up to 25–30 mg/day. International normalized ratio (INR) values never stabilized >2.0 over 4.5 years of therapy. This patient had experienced 3 myocardial infarctions (MIs) and 2 ischemic strokes between the ages of 29 and 31 years and experienced another MI at age 33 years. This was followed by several episodes of transient ischemic attacks at age 34 years. During the final year of warfarin treatment, tobacco use was terminated, followed by an increase in INR values from 1.1 to 2.3 within one week. Warfarin therapy was discontinued and smokeless tobacco use was reinstated and tapered slowly to discontinuation. Following warfarin discontinuation, ticlopidine therapy was initiated. Subsequently, this patient was placed on long-term clopidogrel therapy. Mechanisms responsible for this interaction have not been established, but would most likely involve an increased dietary source of vitamin K from tobacco. DISCUSSION Tobacco contains high levels of vitamin K, and its use may have contributed directly to the failure of warfarin therapy to achieve therapeutic INR levels in this patient. An objective causality scale indicates a probable association between this combination and the adverse effects. Smokeless tobacco use should be charted in patients undergoing warfarin therapy, and patients who desire to stop tobacco use should be aided in this process. CONCLUSIONS Possible health effects of smokeless tobacco may include potential drug interactions. These interactions may be based on pharmacodynamic and/or pharmacokinetic parameters involving any of the many pharmacologically active substituents of tobacco. Proposed mechanisms of drug interaction may include increased vitamin K levels in the diet.

Publisher

SAGE Publications

Subject

Pharmacology (medical)

Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Subtherapeutic INR due to warfarin interaction with smokeless tobacco;Journal of Thrombosis and Haemostasis;2020-09-18

2. Oral Anticoagulant Therapy;Chest;2012-02

3. Nicotine and Tobacco;Handbook of Drug Interactions;2011-07-12

4. Assessing Evidence of Interaction Between Smoking and Warfarin;Chest;2011-05

5. Effects of Specific Foods and Dietary Components on Drug Metabolism;Handbook of Drug-Nutrient Interactions;2009

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3